Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Post by snootchybootchyon Oct 21, 2016 7:50pm
167 Views
Post# 25373238

Concordia

ConcordiaWild volatility in Concordia's share price today as CEO Mark Thompson stepped down.  Opened at $5.43 and went up to $7.39 and then closed back down at $5.98.  I'm thinking the new CEO will likely look to sell off assets.  The new CEO may be willing to sell them at discounted prices since he/she will not be as emotionally invested in these drugs.  I noticed Concordia has a few cardiovascular-related drugs on its roster, which may be attractive to Mr. Adams.

I know I mentioned this before on this board but Jonathan Goodman predicted good deals could be had in Q4 2016 or Q1 2017 as over-leveraged drug companies will be seeking to sell assets in order to de-lever.  And 15 months or so ago when pharmaceutical stocks were going through the roof, frustrated Knight shareholders thought Mr. Goodman was being overly cautious with his trove of cash but he maintained the valuations of the pharma acquisitions at the time were unsustainable.  It's pretty amazing how often his prognostications have turned out to be correct.
<< Previous
Bullboard Posts
Next >>